WO2008123469A1 - Composé amide à six chaînons et son utilisation - Google Patents
Composé amide à six chaînons et son utilisation Download PDFInfo
- Publication number
- WO2008123469A1 WO2008123469A1 PCT/JP2008/056237 JP2008056237W WO2008123469A1 WO 2008123469 A1 WO2008123469 A1 WO 2008123469A1 JP 2008056237 W JP2008056237 W JP 2008056237W WO 2008123469 A1 WO2008123469 A1 WO 2008123469A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amide compound
- membered
- membered amide
- compound
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention porte sur un composé ayant une excellente action inhibitrice de l'activité SCD1. De façon spécifique, l'invention porte sur un composé représenté par la formule générale [B-0'] ci-après, sur un sel pharmaceutiquement acceptable de celui-ci ou sur un solvate de celui-ci. [B-0'] (Dans la formule, les symboles sont tels que définis dans la description).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007095639 | 2007-03-30 | ||
JP2007-095639 | 2007-03-30 | ||
US92581607P | 2007-04-23 | 2007-04-23 | |
US60/925,816 | 2007-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008123469A1 true WO2008123469A1 (fr) | 2008-10-16 |
Family
ID=39830954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/056237 WO2008123469A1 (fr) | 2007-03-30 | 2008-03-28 | Composé amide à six chaînons et son utilisation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008123469A1 (fr) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2202228A1 (fr) * | 2007-10-15 | 2010-06-30 | Takeda Pharmaceutical Company Limited | Composés amides et leur utilisation |
JP2011051931A (ja) * | 2009-09-01 | 2011-03-17 | Sagami Chemical Research Institute | 2−アシルアミノチアゾール誘導体及びその製造方法 |
WO2013056148A2 (fr) | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Procédés d'utilisation d'antagonistes de scd1 |
WO2013061297A1 (fr) * | 2011-10-28 | 2013-05-02 | Pfizer Limited | Dérivés de pyridazine utiles en thérapie |
JP2013544806A (ja) * | 2010-11-01 | 2013-12-19 | ロマーク ラボラトリース,エル.シー. | アルキルスルフィニル置換チアゾリド化合物 |
JP2014520886A (ja) * | 2011-07-18 | 2014-08-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンズアミド類 |
JP2016164177A (ja) * | 2010-08-23 | 2016-09-08 | シントリックス・バイオシステムズ・インコーポレイテッドSyntrix Biosystems, Inc. | Cxcr2モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
US9707248B2 (en) | 2013-08-02 | 2017-07-18 | Syntrix Biosystems Inc. | Use of thiopyrimidinecarboxamide for treating cancer |
WO2018028517A1 (fr) * | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Inhibiteurs d'amino pyrimidine ssao |
US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
JP2018522983A (ja) * | 2015-07-20 | 2018-08-16 | イリドス リミテッド | 着色剤化合物及びこれを含む着色剤材料 |
CN109354580A (zh) * | 2018-11-21 | 2019-02-19 | 山东罗欣药业集团股份有限公司 | 一种盐酸多奈哌齐的制备方法 |
USRE47267E1 (en) | 2009-02-17 | 2019-03-05 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as CXCR2 modulators |
US10278970B2 (en) | 2017-02-14 | 2019-05-07 | Eli Lilly And Company | Amino pyrimidine compounds useful as SSAO inhibitors |
CN103450112B (zh) * | 2013-08-07 | 2019-09-13 | 华东理工大学 | 一种n-桥连接的含氮五元杂环化合物及其制备与用途 |
US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
JP2020524178A (ja) * | 2017-05-24 | 2020-08-13 | ヨハン ヴォルフガング ゲーテ−ウニヴェルズィテート フランクフルト アム マイン | ファルネソイドx受容体および可溶性エポキシドヒドロラーゼの二重調節剤 |
US10973810B2 (en) | 2017-01-06 | 2021-04-13 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
CN113149941A (zh) * | 2020-01-22 | 2021-07-23 | 中国科学院上海药物研究所 | 醚类化合物及其在防治糖尿病及代谢综合征中的药学用途 |
JP2021519263A (ja) * | 2018-03-23 | 2021-08-10 | ユマニティ セラピューティクス,インコーポレーテッド | 化合物及びその使用 |
US11820754B2 (en) | 2020-08-25 | 2023-11-21 | Eli Lilly And Company | Polymorphs of an SSAO inhibitor |
US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006034279A1 (fr) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Derives heterocycliques et leur utilisation comme agents therapeutiques |
WO2006085685A1 (fr) * | 2005-02-09 | 2006-08-17 | Takeda Pharmaceutical Company Limited | Dérivé de pyrazole |
-
2008
- 2008-03-28 WO PCT/JP2008/056237 patent/WO2008123469A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006034279A1 (fr) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Derives heterocycliques et leur utilisation comme agents therapeutiques |
WO2006085685A1 (fr) * | 2005-02-09 | 2006-08-17 | Takeda Pharmaceutical Company Limited | Dérivé de pyrazole |
Non-Patent Citations (1)
Title |
---|
SHIPPS G.W. ET AL.: "Aminothiazole inhibitors of HCV RNA polymerase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, no. 1, 2005, pages 115 - 119, XP004668761 * |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2202228A1 (fr) * | 2007-10-15 | 2010-06-30 | Takeda Pharmaceutical Company Limited | Composés amides et leur utilisation |
EP2202228A4 (fr) * | 2007-10-15 | 2011-06-29 | Takeda Pharmaceutical | Composés amides et leur utilisation |
US8329691B2 (en) | 2007-10-15 | 2012-12-11 | Takeda Pharmaceutical Company Limited | Amide compounds and use of the same |
USRE47267E1 (en) | 2009-02-17 | 2019-03-05 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as CXCR2 modulators |
USRE47415E1 (en) | 2009-02-17 | 2019-06-04 | Syntrix Biosystems, Inc. | Pyrimidinecarboxamides as CXCR2 modulators |
JP2011051931A (ja) * | 2009-09-01 | 2011-03-17 | Sagami Chemical Research Institute | 2−アシルアミノチアゾール誘導体及びその製造方法 |
JP2019069946A (ja) * | 2010-08-23 | 2019-05-09 | シントリックス・バイオシステムズ・インコーポレイテッドSyntrix Biosystems, Inc. | Cxcr2モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
USRE47740E1 (en) | 2010-08-23 | 2019-11-26 | Syntrix Biosystems Inc. | Aminopyridinecarboxamides as CXCR2 modulators |
JP2016164177A (ja) * | 2010-08-23 | 2016-09-08 | シントリックス・バイオシステムズ・インコーポレイテッドSyntrix Biosystems, Inc. | Cxcr2モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
USRE48547E1 (en) | 2010-08-23 | 2021-05-11 | Syntrix Biosystems Inc. | Aminopyrimidinecarboxamides as CXCR2 modulators |
JP2013544806A (ja) * | 2010-11-01 | 2013-12-19 | ロマーク ラボラトリース,エル.シー. | アルキルスルフィニル置換チアゾリド化合物 |
JP2014520886A (ja) * | 2011-07-18 | 2014-08-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンズアミド類 |
US9938262B2 (en) | 2011-07-18 | 2018-04-10 | Merck Patent Gmbh | Benzamides |
US9358250B2 (en) | 2011-10-15 | 2016-06-07 | Genentech, Inc. | Methods of using SCD1 antagonists |
WO2013056148A2 (fr) | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Procédés d'utilisation d'antagonistes de scd1 |
CN103958481A (zh) * | 2011-10-28 | 2014-07-30 | 因西必泰克新有限公司 | 可用于治疗的哒嗪衍生物 |
JP2014530902A (ja) * | 2011-10-28 | 2014-11-20 | インヒビタクシン リミテッド | 治療に有用なピリダジン誘導体 |
US10016420B2 (en) | 2011-10-28 | 2018-07-10 | Inhibitaxin Limited | Substituted pyridazines for the treatment of pain |
WO2013061297A1 (fr) * | 2011-10-28 | 2013-05-02 | Pfizer Limited | Dérivés de pyridazine utiles en thérapie |
US9273011B2 (en) | 2011-10-28 | 2016-03-01 | Inhibitaxin Limited | Substituted pyridazines for the treatment of pain |
CN106220572A (zh) * | 2011-10-28 | 2016-12-14 | 因西必泰克新有限公司 | 哒嗪衍生物的化合物、用途、组合物和试剂盒及制备方法 |
US9707248B2 (en) | 2013-08-02 | 2017-07-18 | Syntrix Biosystems Inc. | Use of thiopyrimidinecarboxamide for treating cancer |
US10130645B2 (en) | 2013-08-02 | 2018-11-20 | Syntrix Biosystems, Inc. | Use of thiopyrimidinecarboxamide for treating cancer |
US10993953B2 (en) | 2013-08-02 | 2021-05-04 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
CN103450112B (zh) * | 2013-08-07 | 2019-09-13 | 华东理工大学 | 一种n-桥连接的含氮五元杂环化合物及其制备与用途 |
JP2018522983A (ja) * | 2015-07-20 | 2018-08-16 | イリドス リミテッド | 着色剤化合物及びこれを含む着色剤材料 |
JP2021091904A (ja) * | 2015-07-20 | 2021-06-17 | イリドス リミテッド | 着色剤化合物及びこれを含む着色剤材料 |
KR20190038580A (ko) * | 2016-08-12 | 2019-04-08 | 일라이 릴리 앤드 캄파니 | 아미노 피리미딘 ssao 억제제 |
KR102483876B1 (ko) | 2016-08-12 | 2023-01-03 | 일라이 릴리 앤드 캄파니 | 아미노 피리미딘 ssao 억제제 |
US10464928B2 (en) | 2016-08-12 | 2019-11-05 | Eli Lilly And Company | Amino pyrimidine SSAO inhibitors |
US10287270B2 (en) | 2016-08-12 | 2019-05-14 | Eli Lilly And Company | Amino pyrimidine SSAO inhibitors |
KR102646063B1 (ko) | 2016-08-12 | 2024-03-12 | 일라이 릴리 앤드 캄파니 | 아미노 피리미딘 ssao 억제제 |
KR20230008889A (ko) * | 2016-08-12 | 2023-01-16 | 일라이 릴리 앤드 캄파니 | 아미노 피리미딘 ssao 억제제 |
AU2017309199B2 (en) * | 2016-08-12 | 2022-05-12 | Eli Lilly And Company | Amino pyrimidine SSAO inhibitors |
US10793552B2 (en) | 2016-08-12 | 2020-10-06 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
CN114380801A (zh) * | 2016-08-12 | 2022-04-22 | 伊莱利利公司 | 氨基嘧啶ssao抑制剂及其制备方法 |
WO2018028517A1 (fr) * | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Inhibiteurs d'amino pyrimidine ssao |
US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
US10973810B2 (en) | 2017-01-06 | 2021-04-13 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
US10278970B2 (en) | 2017-02-14 | 2019-05-07 | Eli Lilly And Company | Amino pyrimidine compounds useful as SSAO inhibitors |
US10471060B2 (en) | 2017-02-14 | 2019-11-12 | Eli Lilly And Company | Amino pyrimidine compounds useful as SSAO inhibitors |
JP2020524178A (ja) * | 2017-05-24 | 2020-08-13 | ヨハン ヴォルフガング ゲーテ−ウニヴェルズィテート フランクフルト アム マイン | ファルネソイドx受容体および可溶性エポキシドヒドロラーゼの二重調節剤 |
US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
JP2021519263A (ja) * | 2018-03-23 | 2021-08-10 | ユマニティ セラピューティクス,インコーポレーテッド | 化合物及びその使用 |
CN109354580A (zh) * | 2018-11-21 | 2019-02-19 | 山东罗欣药业集团股份有限公司 | 一种盐酸多奈哌齐的制备方法 |
CN109354580B (zh) * | 2018-11-21 | 2020-08-07 | 山东罗欣药业集团股份有限公司 | 一种盐酸多奈哌齐的制备方法 |
CN113149941A (zh) * | 2020-01-22 | 2021-07-23 | 中国科学院上海药物研究所 | 醚类化合物及其在防治糖尿病及代谢综合征中的药学用途 |
US11820754B2 (en) | 2020-08-25 | 2023-11-21 | Eli Lilly And Company | Polymorphs of an SSAO inhibitor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008123469A1 (fr) | Composé amide à six chaînons et son utilisation | |
WO2008120759A1 (fr) | Composé d'urée et son utilisation | |
WO2009060835A8 (fr) | Nouvelle petite molécule de liaison de l'ubiquitine | |
WO2008153159A1 (fr) | Composé aminé et son utilisation pharmaceutique | |
WO2009028629A1 (fr) | Composé hétérocyclique et son utilisation | |
WO2009057079A3 (fr) | Nouveaux dérivés de pyrimidine | |
WO2009025358A1 (fr) | Composé hétérocyclique et son utilisation | |
EP1864665A4 (fr) | Agent immunosuppressif et agent anti-tumoral comprenant un compose heterocyclique en tant que principe actif | |
EP1736465A4 (fr) | Dérivés d'aniline | |
WO2008120725A1 (fr) | Nouveau dérivé de pyrrolinone et composition médicale le contenant | |
WO2008075068A3 (fr) | Nouveaux composés | |
WO2008142055A3 (fr) | Agents antiviraux | |
WO2007135527A3 (fr) | Composés de benzimidazolyle | |
TN2010000148A1 (en) | Amide compound | |
EP1889842A4 (fr) | Composé hétérocyclique | |
WO2007014054A3 (fr) | Inhibiteur benzenesulfonamide de recepteur de chimiokine ccr2 | |
WO2009051244A1 (fr) | Composé hétérocyclique | |
WO2007136759A3 (fr) | Procédé de traitement et de prévention de troubles oculaires | |
WO2009016560A3 (fr) | Dérivés de trans-3-aza-bicyclo[3.1.0]hexane | |
WO2008096820A1 (fr) | Dérivé diphényle | |
WO2008008718A3 (fr) | Composés thérapeutiques | |
WO2010066629A3 (fr) | Nouvelles azaindoles | |
WO2006041631A3 (fr) | Alcynes de cyclosporine, et leur utilite comme agents pharmaceutiques | |
WO2009064374A3 (fr) | Formulations orales de bis(thiohydrazideamides) | |
WO2009020137A1 (fr) | Dérivé d'aminopyrazole amide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08739355 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08739355 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |